Compound Screening TRIZ Cases

Segmented immunoassays distinguish active parathyroid hormone from inactive oxidized forms to resolve measurement inaccuracies in uraemic patients.

Cells expressing mortalin and Hsp60 identify compounds altering protein levels to regulate melanogenesis.

Characterizing T-bet phosphorylation at S508 resolves mechanism gaps, enabling targeted modulation of IL-2 production in Th1 cells.

Antibodies detect Spot 14 protein levels in breast cancer tissue samples to guide therapeutic selection.

A peptide array detects antibody binding patterns to identify unique immunosignatures associated with specific diseases.

Isolate the CARD domain from caspase-4 to screen specific inhibitors that block lipopolysaccharide binding, avoiding off-target effects on other caspases.

Specific polypeptide antigens target Neisseria gonorrhoeae to resolve ineffective treatment protocols and prevent infertility.

Peptoids bind specific antibody subtypes to detect Alzheimer's disease biomarkers, enabling early diagnosis despite limited existing markers.

Computational maturation matrix translates immature cardiomyocyte voltage and calcium data into mature cell predictions.

A soluble lipid analog with a fluorescence activating moiety binds to integral membrane proteins.

FRET and BRET assays detect sortilin binding antagonists through fluorescence energy transfer ratios.

Humanized antibodies targeting glucose transporter 8 resolve immune rejection risks while maintaining high selectivity for cancer cell destruction.

Ipatasertib inhibits the AKT signaling pathway in skin-specific T cells, reducing serum IgE and skin lesions without systemic immune suppression.

Yeast cells co-expressing nanobodies stabilize membrane proteins during production.

Detectable labeled polypeptide substrates enable O-glycosylation monitoring via protease cleavage signals.

Time-resolved FRET measurements isolate modulator signals from intracellular noise, improving detection precision without complex screening systems.

Cathepsin L inhibitors stabilize actin structures in podocytes to prevent proteinuria.

Segmenting the CMV virion into specific proteins creates subunit vaccines that neutralize the virus in epithelial cells without using live strains.

Residue-based pharmacophore method identifies cognate protein ligands by correlating molecular dynamics sampling with free energy to reduce testable hypotheses.

Targeting the TRPM4 ion channel with specific compounds resolves neuro-axonal degeneration and reduces clinical disability in multiple sclerosis.

Labeled RNA molecules bind to substrates for automated snRNP assembly detection, resolving quantitative analysis limits in spinal muscular atrophy research.

A multi-marker biomarker signature classifies inflammatory bowel disease patients to predict anti-TNF therapy response.

A pharmaceutical composition inhibits CCR6 receptor activity to block CCL18-induced signaling pathways.

Modified anti-IL-6 receptor antibodies with specific amino acid mutations in variable and constant regions enhance antigen binding.

Selecting probiotic strains with specific enzymatic activities to ferment olive polyphenols into absorbable metabolites.

A competitive isoTOP-ABPP method quantifies electrophile reactivity against cysteine residues in human proteomes.

Engineered hERG channel proteins enable high-throughput screening via liposome flux assays using pH-sensitive fluorescent dyes.

Adding a Fyn lipidation tag moves trapped TMC1 and TMC2 proteins from the endoplasmic reticulum to the cell surface, enabling mechanosensitive channel activity.

UNE-L domain of leucyl-tRNA synthetase activates mTORC1 signaling to promote muscle protein synthesis and fiber regeneration.

Chemical activation of ubiquitin via small molecule thiols bypasses ATP and E2 enzymes, resolving assay complexity while maintaining physiological relevance.

A competitive binding-LC-MS workflow identifies product-related variants in therapeutic proteins by analyzing flow-through from insufficient capture assays.

Disrupting the LINC complex in skin cells eliminates scaffold complexity while enabling scaffold-free tissue formation.

Crystal structure of PBP1b with moenomycin identifies binding residues to enable rational drug design against resistant bacteria.

Cyclic peptides bind the K-Ras G12D oncoprotein using click chemistry, bypassing the need to outcompete GTP for the native binding pocket.

Monoclonal antibodies targeting the hCMV UL128-UL130-UL131A protein complex achieve high potency neutralization across diverse host cell types.

Peptides derived from cadherin bind presenilin-1 to block gamma-secretase cleavage.

Targeted inhibitors disrupt EGFR-SAR1A binding to overcome resistance in cancer therapy.

Glycoconjugate vaccines overcome pathogen diversity by targeting conserved oligomannose epitopes to elicit broadly neutralizing antibodies.

Methacrylated hyaluronic acid bioink crosslinks into stable hydrogel scaffolds, resolving high viscosity issues in extrusion bioprinting.

A method evaluates cellulite using fibulin-3 and sarcoglycan gamma expression levels as molecular indicators in skin tissue samples.